LEI105
LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL) -α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation[1].
Product Specifications
CAS Number
1800327-36-9
UNSPSC
12352005
Target
DAGL
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lei105.html
Smiles
O=C(C1=NC2=NC=C(C3=CC=C(C)C=C3)C=C2O1)CCCCCC4=CC=CC=C4
Molecular Formula
C25H24N2O2
Molecular Weight
384.47
References & Citations
[1]Baggelaar MP, et al. Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. J Am Chem Soc. 2015 Jul 15;137 (27) :8851-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC881805-100 1x 100 µL
GP2 (Glycoprotein 2) / ZAP75 (GP2/1805), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
LC401671 20 µg
FAIM3 (FCMR) (NM_005449) Human Over-expression Lysate
Sign In for Pricing
View Details 
RD-MC4R-Hu-01 96 Tests
Human Melanocortin 4 Receptor (MC4R) ELISA Kit
Sign In for Pricing
View Details